Adding the Hepcidin Mimetic Rusfertide to the Standard of Care Yields Benefits in Polycythemia Vera

The phase III VERIFY study revealed that rusfertide, a hepcidin mimetic, significantly improves treatment outcomes for polycythemia vera patients requiring frequent phlebotomies. Presented by Dr. Andrew Kuykendall, the study showed that rusfertide more than doubled the response rate and enhanced quality of life by reducing the frequency of phlebotomies, maintaining better hematocrit control, and alleviating symptoms like fatigue. The ongoing trial will further validate rusfertide's effectiveness as a potential standard treatment option for this chronic blood disorder.